GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lixte Biotechnology Holdings Inc (FRA:8640) » Definitions » DeferredTaxAndRevenue

Lixte Biotechnology Holdings (FRA:8640) DeferredTaxAndRevenue

: €0.14 Mil (As of Dec. 2023)
View and export this data going back to 2021. Start your Free Trial

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Lixte Biotechnology Holdings's current deferred tax and revenue for the quarter that ended in Dec. 2023 was €0.14 Mil.

Lixte Biotechnology Holdings DeferredTaxAndRevenue Historical Data

The historical data trend for Lixte Biotechnology Holdings's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lixte Biotechnology Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
DeferredTaxAndRevenue
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.01 0.07 0.16 0.14

Lixte Biotechnology Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
DeferredTaxAndRevenue Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.02 0.03 0.09 0.14

Lixte Biotechnology Holdings DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of Lixte Biotechnology Holdings's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Lixte Biotechnology Holdings (FRA:8640) Business Description

Traded in Other Exchanges
Address
680 East Colorado Boulevard, Suite 180, Pasadena, CA, USA, 91101
Lixte Biotechnology Holdings Inc is a drug discovery company that has a developed unique, proprietary, first-in-class protein phosphatase inhibitor, LB-100, as its lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in combination with standard anti-cancer therapies, including cytotoxic drugs, radiation, and immune checkpoint blockers. The Company's product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and x-ray and immune checkpoint blockers.

Lixte Biotechnology Holdings (FRA:8640) Headlines

No Headlines